Sanuwave Announces Q2 FY2026 Financial Results

Sanuwave Health (NASDAQ: SNWV) reported Q2 2026 revenues of $9.7 million, down 3% year-over-year, with gross margins declining to 76.2% from 78.1%. The company posted an operating loss of $0.3 million versus operating income of $1.4 million in Q2 2025. While Ultramist applicator revenue grew 13%, system sales declined significantly due to CMS reimbursement pressures and a secondary market for used equipment. The company has withdrawn its 2026 guidance pending clarity on Medicare reimbursement developments.